June 26, 2017 4:25 AM ET


Company Overview of Kedrion S.p.A.

Company Overview

Kedrion S.p.A. develops, manufactures, and distributes blood plasma-derived therapeutic products in the areas of hematology/hemophilia, immunology/neurology, and critical care, as well as pharmacovigilance therapies. It collects and fractionates blood plasma to produce and distribute plasma-derived therapeutic products for use in treating serious diseases, disorders, and conditions, such as hemophilia and immune system deficiencies. The company also engages in orphan drug research and development activities; offers contract manufacturing and technology transfer services; and conducts virus and prion safety studies on products and manufacturing processes. It serves customers and partners prim...

Loc. Ai Conti

Castelvecchio Pascoli

Barga, LU 55051


Founded in 2001

1,000 Employees


39 058 319691


39 05 83 76 61 21

Key Executives for Kedrion S.p.A.

Chairman, Chief Executive Officer, President and Managing Director
Chief Communication Officer
General Manager
Industrial Director
Institutional Affairs Director
Compensation as of Fiscal Year 2016.

Kedrion S.p.A. Key Developments

Kedrion S.p.A., Annual General Meeting, Apr 27, 2017

Kedrion S.p.A., Annual General Meeting, Apr 27, 2017. Agenda: To approve financial statements for the year 2016.

Kedrion SpA Announces Consolidated Earnings Results for the Year 2016

Kedrion SpA announced consolidated earnings results for the year 2016. For the year, the company reported turnover of EUR 659.3 million and a growth of EUR 89 million, an increase by 15.6%, compared to the previous financial year. Adjusted EBITDA was EUR 106.3 million against EUR 118.9 million in 2015, whereas EBIT ­ affected by the significant one-off costs of the revamping operations at the US plant ­ is EUR 19.8 million, or 3.0% of turnover. Net income is EUR 11.8 million, equal to 1.8% of total turnover.

Kedrion, Pharmstandard and Natsimbio to Form Joint Venture for Plasma-Derived Medicinal Products

Kedrion announced that it is forming a joint venture together with Natsimbio and Pharmstandard to establish a factory in Russia. The companies have agreed to complete the construction of the plant in Kirov by 2019. The investment in the factory is set to reach RUB 4 billion. Kedrion will have a 25% stake in the joint venture, with the Russian companies each having a 37.5% stake.

Similar Private Companies By Industry

Company Name Region
AdriaCell Srl Europe
AEB SPA Europe
APAvadis Biotechnologies Europe
Arterra Bioscience s.r.l. Europe
Axxam SpA Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Kedrion S.p.A., please visit www.kedrion.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.